top of page

2022 Rome Action Plan on Paediatric HIV & TB

Laurus Labs

HIV MEDICINES FOR CHILDREN

Laurus Labs commits to:

​

240. Collaborating with regulators and clinicians to obtain data on the ease of administration of oral films in neonates and the paediatric population by 2024.

​

241. Expanding the oral film technology to other HIV products as well as TB and malaria.

​

242. Allocating resources to develop DRV and TAF containing FDCs for the paediatric use beginning Q2 2023.

Updates

 - 

​

​

bottom of page